Methods and systems for classification and treatment of small cell lung cancer
Patent Information
- Application Number
- JP2023527276
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Claims
1. A composition for treating a subject for small cell lung cancer (SCLC), comprising a targeting agent capable of specifically binding to DLL3, CEACAM5, or SCNN1A, or a targeting agent capable of specifically binding to one or more of the proteins in Table 1, Table 2, or Table 3, wherein the subject is determined to have SCLC-A.
2. The composition of claim 1, wherein the targeting agent is capable of specifically binding to DLL3, CEACAM5, or SCNN1A.
3. The composition of any one of claims 1 to 2, wherein the subject is determined to have SCLC-A by detecting expression of ASCL1 from cancer cells derived from the subject.
4. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to CD276 or a targeting agent capable of specifically binding to one or more of the proteins in Table 10, Table 11, or Table 12, wherein the subject has been determined to have SCLC-I.
5. The composition of claim 4, wherein the targeting agent is capable of specifically binding to SLAMF8, MRC2, or PIEZO1.
6. The composition of any one of claims 4 to 5, wherein the subject has been determined to have SCLC-I by confirming that cancer cells derived from the subject do not express any of POU2F3, NEUROD1, or ASCL1.
7. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to SEZ6 or a targeting agent capable of specifically binding to one or more of the proteins of Table 4, Table 5, or Table 6, wherein the subject has been determined to have SCLC-N.
8. The composition of claim 7, wherein the targeting agent is capable of specifically binding to SSTR2, SEMA6D, or SGCD.
9. The composition according to any one of claims 7 to 8, wherein the subject is determined to have SCLC-N by detecting expression of NEUROD1 from cancer cells derived from the subject.
10. A composition for treating a subject for SCLC, the composition comprising a targeting agent capable of specifically binding to TACSTD2 or a targeting agent capable of specifically binding to one or more of the proteins in Table 7, Table 8, or Table 9, wherein the subject has been determined to have SCLC-P.
11. The composition of claim 10, wherein the targeting agent is capable of specifically binding to MICA, TMEM87A, or ART3.
12. The composition of any one of claims 10 to 11, wherein the subject is determined to have SCLC-P by detecting expression of POU2F3 from cancer cells derived from the subject.
13. The composition of any one of claims 1 to 12, wherein the targeting agent comprises an antibody or a fragment thereof.
14. The composition of any one of claims 1 to 12, wherein the targeting agent is a bispecific T cell engager.
15. The composition of any one of claims 1 to 14, wherein the composition comprises cells containing a targeting agent.
16. The composition of claim 15, wherein the cell is an immune cell.
17. The composition of claim 16, wherein the immune cell is a T cell or a NK cell.
18. The composition of any one of claims 15 to 17, wherein the targeting agent is a chimeric antigen receptor or a T cell receptor.
19. The composition of any one of claims 1 to 18, wherein the targeting agent is operably linked to a therapeutic agent.
20. 20. The composition of claim 19, wherein the therapeutic agent is a chemotherapeutic agent, a toxin, or a therapeutic nucleic acid.
21. The composition of any one of claims 1 to 20, wherein the targeting agent is an antibody-drug conjugate or an antibody-oligonucleotide conjugate.
